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Abstract
Background: Mefloquine has historically been considered safe and well-tolerated for long-term
malaria chemoprophylaxis, but its prescribing requires careful attention to rule out
contraindications to its use, including a history of certain psychiatric and neurological disorders.
The prevalence of these disorders has not been defined in cohorts of U.S. military personnel
deployed to areas where long-term malaria chemoprophylaxis is indicated.
Methods:  Military medical surveillance and pharmacosurveillance databases were utilized to
identify contraindications to mefloquine use among a cohort of 11,725 active duty U.S. military
personnel recently deployed to Afghanistan.
Results: A total of 9.6% of the cohort had evidence of a contraindication. Females were more than
twice as likely as males to have a contraindication (OR = 2.48, P < 0.001).
Conclusion: These findings underscore the importance of proper systematic screening prior to
prescribing and dispensing mefloquine, and the need to provide alternatives to mefloquine suitable
for long-term administration among deployed U.S. military personnel.
Background
Malaria poses a continued threat to U.S. military person-
nel. At least 423 blood-smear confirmed cases of malaria
were diagnosed among members of the U.S. military
between January 1st, 2000 and December 31st, 2005; of
which at least 64 represent cases attributable to service in
Afghanistan [1]. Outbreaks of malaria among U.S. mili-
tary personnel attributable to service in Afghanistan are
well described [1,2], of which infection due to Plasmodium
vivax is the principal cause. To protect against the threat of
malaria, U.S. military personnel deploying to Afghanistan
may be prescribed mefloquine, which must be taken con-
tinuously throughout deployments lasting as long as 15
months. Although the long-term use of mefloquine for
malaria chemoprophylaxis has historically been consid-
ered safe and well-tolerated among civilian travelers [3,4]
and deployed military personnel [5], careful prescribing is
needed to minimize the potential for severe neuropsychi-
atric adverse events, which may include acute psychoses,
anxiety, depression, paranoia, myoclonus, and seizures
[5]. Although the underlying mechanism of these adverse
events is unknown, individuals with certain psychiatric
and neurological histories appear to be at highest risk
[4,5]. The U.S. package insert cautions that mefloquine
"should not be prescribed for prophylaxis in patients with
active depression, a recent history of depression, general-
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ized anxiety disorder, psychosis, or schizophrenia or other
major psychiatric disorders, or with a history of convul-
sions" [6].
To quantify the prevalence of, and identify demographic
characteristics associated with contraindications to meflo-
quine use among deployed U.S. military personnel, a ret-
rospective cohort study was performed using information
available in military personnel, medical surveillance
[1,4,7], and pharmacosurveillance databases [4,8].
Methods
Study population
To identify the study cohort, a roster was obtained com-
prising all active duty U.S. military personnel assigned in
support of combat and reconstruction operations in
Afghanistan and deployed within six months of a refer-
ence date in early 2007. Demographic covariate data on
each was obtained from the Defense Medical Surveillance
System (DMSS) [7], to include age category (as of the ref-
erence date), race (categorized as black, white, and other),
gender, number of prior deployments, and military spe-
cialty (categorized as combat, and non-combat according
to methods previously described) [5].
Medical contraindications
For each member of the study cohort, DMSS was queried
for International Classification of Diseases, Ninth Revi-
sion, Clinical Modification (ICD-9CM) -coded [9] diag-
noses from inpatient and outpatient visits occurring
within the 365 days prior to the date of deployment, con-
sistent with psychiatric and neurological contraindica-
tions to mefloquine use [6]. These included depression,
generalized anxiety disorder, psychosis, schizophrenia,
and other major psychiatric disorders, which were defined
to include bipolar disorders, obsessive-compulsive disor-
ders, panic disorders, attention-deficit and attention-defi-
cit hyperactivity disorders (ADHD), dissociative,
conversion and factitious disorders, delusional disorders,
and post-traumatic stress disorder. Also included as indic-
ative of depression were adjustment disorders with
depressed mood, dysthymic disorders, and cyclothymic
personality disorder. Specifically excluded were drug and
alcohol-related disorders; transient, acute or poorly-
defined conditions; non-specific phobic disorders and
non-depressive personality disorders, sexual and gender
identity disorders, and somatoform diagnoses. Specific
neurological diagnoses consistent with a liberal interpre-
tation of a history of convulsions were included, to
include Parkinson's disease, extrapyramidal diseases and
other movement disorders, and epilepsy. A full list of
diagnoses used to define a medical contraindication is
provided as Table 1.
Pharmacologic contraindications
For each member of the study cohort, Pharmacy Data
Transaction System (PDTS) records [8] were examined for
prescription drugs dispensed at military, retail and mail-
order pharmacies within the 180 days prior to deploy-
ment, whose use would be consistent with the treatment
of psychiatric and neurological contraindications. These
prescription drugs included ADHD treatments, antipsy-
chotics, anticonvulsants, antiparkinsonians, sedative-anx-
iolytics, and antidepressants. Specifically excluded were
amantadine, antidepressants commonly prescribed for
smoking cessation (buproprion), as were the short-acting
hypnotics commonly prescribed as sleep-aids. A full list of
prescription drugs used to define a pharmacologic con-
traindication is provided as Table 2.
Statistical methods
Analyses included producing summary and descriptive
statistics. The prevalence and the statistical significance of
associations between demographic characteristics and a
contraindication to mefloquine use were determined. All
statistical analyses, including producing Pearson's χ2 sta-
tistics, P-values, calculation of crude odds ratios (ORs)
and associated 95% confidence intervals (CIs) were per-
formed using SAS software (Version 9.1; SAS Institute,
Cary, NC) [10].
Table 1: Medical diagnoses consistent with contraindication to 
mefloquine use.
Diagnosis ICD-9CM Codes
Major depressive disorder 296.2–296.3
Adjustment disorder with 
depressed mood
309.0, 309.28
Prolonged depressive reaction 309.1
Dysthymic disorder 300.4
Depression 311
Cyclothymic disorder 301.13
Generalized anxiety disorder 300.02
Psychoses (non-organic) 298
Schizophrenia 295
Bipolar and manic disorders 296.0, 296.1, 296.3–296.8
Obsessive-compulsive disorder 300.3
Panic disorder (with and without 
agorophobia)
300.01, 300.21
Attention-deficit disorders (with 
or without hyperactivity)
314.0
Dissociative, conversion and 
factitious disorders
300.1
Delusional disorders 297
Post-traumatic stress disorder 309.81
Parkinsonism 332
Extrapyramidal diseases and 
movement disorders
333
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Results
The study cohort consisted of 11,725 subjects. A total of
558 subjects (4.8%) had a medical contraindication (i.e.
one or more psychiatric or neurological diagnoses prior to
deployment consistent with a contraindication to meflo-
quine use). A total of 837 (7.1%) had a pharmacologic
contraindication (i.e. one or more prescriptions filled
prior to deployment for medications consistent with a
contraindication to mefloquine use). A total of 1,127
(9.6%) had either or both (i.e. at least one or more such
diagnosis or at least one or more prescription) (Table 3),
comprising 916 males (8.6%) and 211 females (19.0%).
Of the 558 total with one or more diagnoses, 27 (4.8%)
had neurological diagnoses and 531 (95.2%) had psychi-
atric diagnoses. The groups were mutually exclusive.
Among those with neurological diagnoses (0.2% of the
study cohort), all 27 had outpatient diagnoses, and none
had inpatient diagnoses. Of the 27, 13 (48%) had primary
diagnoses. Among those with psychiatric diagnoses (4.5%
of the study cohort), three had inpatient diagnoses, and
the remainder had one or more outpatient diagnoses, of
which 411 (78%) had primary diagnoses.
Of the 837 with one or more prescriptions, 78 (9.4%) had
a prescription for an ADHD treatment; 93 (11.1%) for an
anticonvulsant; 315 (37.6%) for an antidepressant; two
(0.2%) for an antiparkinsonian; 24 (2.9%) for an antipsy-
chotic; and 446 (53.3%) for a sedative-anxiolytic. A total
Table 2: Prescription drugs consistent with a contraindication to mefloquine use
ADHD Treatments
Amphetamines, atomoxetine, methyphenidate, modafinil
Anticonvulsants
Carbamazepine, clonazepam, divalproex sodium, gabapentin, lamotrigine, levetiracetam, oxcarbazepim, phenytoin, pregabalin, topiramate
Antidepressants
Citalopram, duloxetine, escitalopram, fluoxetine, flurazepam, mirtazapine, nefazodone, nortriptyline, paroxetine, sertraline, venlafexine
Antiparkinsonians
Bromocriptine, ropinirole
Antipsychotics
Aripiprazole, haloperidol, olanzapine, olanzapine/fluoxetine, quetiapine, risperidone
Sedatives – anxiolytics
Alprazolam, buspirone, chlordiazepoxide, diazepam, lorazepam, oxazepam, temazepam, trazodone, triazolam
Table 3: Demographics of the study cohort and those with a medical or pharmacologic contraindication to mefloquine use, U.S. 
military personnel deployed to Afghanistan, 2007.
Contraindication(s) to mefloquine
Study cohort Medical Pharmacologic Either or Both
Number (%) Number (%) Number (%) Number (%)
Total 11725 (100) 558 (100) 837 (100) 1127 (100)
Gender
Male 10614 (90.5) 463 (83.0) 670 (80.0) 916 (81.3)
Female 1111 (9.5) 95 (17.0) 167 (20.0) 211 (18.7)
Race
White 8552 (72.9) 428 (76.7) 626 (74.8) 846 (75.1)
Black 1967 (16.8) 84 (15.1) 118 (14.1) 171 (15.2)
Other 1206 (10.3) 46 (8.2) 93 (11.1) 110 (9.8)
Prior deployments
0 7119 (60.7) 315 (56.5) 494 (59.0) 660 (58.6)
1 3442 (29.4) 175 (31.4) 256 (30.6) 347 (30.8)
2+ 1164 (9.9) 68 (12.2) 87 (10.4) 120 (10.6)
Military specialty
Combat 2818 (24.0) 112 (20.1) 153 (18.3) 214 (19.0)
Non-combat 8907 (76.0) 446 (79.9) 684 (81.7) 913 (81.0)
Age
18–19 521 (4.4) 27 (4.8) 18 (2.2) 38 (3.4)
20–29 7701 (65.7) 356 (63.8) 508 (60.7) 702 (62.3)
30–39 2774 (23.7) 138 (24.7) 240 (28.7) 301 (26.7)
40–49 688 (5.9) 37 (6.6) 66 (7.9) 81 (7.2)
50+ 41 (0.3) 0 (0.0) 5 (0.6) 5 (0.4)Malaria Journal 2008, 7:30 http://www.malariajournal.com/content/7/1/30
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of 100 (11.9%) had prescriptions for two or more classes
of drug.
There were significant differences between the study
cohort and those with diagnoses by gender (χ2 = 38.9, P <
0.001) and military specialty (χ2 = 3.44, P = 0.025), and
between the study cohort and those with prescriptions by
gender (χ2 = 115, P < 0.001), military specialty (χ2 = 16.3,
P  ≤ 0.001), and age category (χ2 > 1000, P < 0.001).
Between the study cohort and those with either diagnosis
or prescription, there were significant differences by gen-
der (χ2 = 124, P < 0.001), military specialty (χ2 = 17.4, P <
0.001), and age category (χ2 = 14.3, P < 0.001). Women
had over twice the odds of having either diagnosis or pre-
scription (OR = 2.48, 95% CI 2.11–2.93). Among those
with any deployment history, the odds of either diagnosis
or prescription was higher, but this difference was not sta-
tistically significant (OR = 1.10, 95% CI 0.975–1.25).
Discussion
This is the first study to assess the prevalence of contrain-
dications to mefloquine use among U.S. service members
deployed to a malarious area and for whom long-term
chemoprophylaxis against Plasmodium vivax is indicated.
This study found a high prevalence of contraindications to
the safe use of this drug in this population overall, and a
statistically significant elevation in the prevalence of con-
traindications among females.
This study was performed to determine the prevalence of
contraindications to mefloquine use in a deployed U.S.
military cohort, and as such has a number of limitations
that preclude its generalizability to the non-military U.S.
population. This study examined a highly biased sample
of young adults (93.8% who were under the age of 40),
self-selected for military service from the U.S. general pop-
ulation and subject to considerable selection pressures
from commissioning, enlistment, or periodic health
screenings. These pressures would ordinarily result in this
population being generally more healthy than members
of the U.S. civilian population, and would ordinarily be
expected to reduce the prevalence of health conditions
incompatible with continued military service and deploy-
ment.
Interestingly, this bias, which is commonly referred to as
the "healthy-warrior effect" [11] may not be applicable in
this study population for those health conditions consist-
ent with a contraindication to mefloquine use. The preva-
lences of both acute and chronic mental health diagnoses
are high among cohorts of previously deployed service
members [12,13], although in this study population a sta-
tistically significant difference was not found in the prev-
alence of contraindications among those with and
without such deployment history.
Despite the substantial differences in health histories and
demographics between studies, this study finds a similar
overall rate of contraindication to mefloquine use as a
prior prospective study in the general population, in
which 9% of 2,389 civilian travelers with available medi-
cal histories presenting to a travel medicine clinic were
evaluated [14]. Similar to the present study, this prior
study found a history of psychiatric contraindication in
3.5% of the group. Unlike the present study, in which
neurological contraindications were rare, these were
present in 5.7% of the prior study group. This difference
likely reflects the incompatibility of most neurological
conditions with military service.
This study employed medical surveillance databases to
identify an arbitrary set of ICD-9CM diagnosis codes
defining a medical contraindication to mefloquine use.
The diagnosis codes were selected based on the clinical
judgment of the study authors. This methodology reflects
the clinical uncertainty faced by individual healthcare
providers in interpreting the mefloquine package insert.
Of the listed contraindications to mefloquine use, the
terms "major psychiatric disorders" and "history of con-
vulsions" leave significant room for interpretation. In this
study, a liberal interpretation of neurological disorder,
and a relatively conservative interpretation of psychiatric
disorder were employed. This had the effect of including
and excluding, respectively, many diagnoses which indi-
vidual providers might or might not consider a contrain-
dication.
The use of pharmacosurveillance databases to infer the
presence of a contraindicating medical condition is rea-
sonable. Previous studies [8] have shown significant cor-
relation between psychiatric diagnosis and psychoactive
drug prescription, and the dispensing of a drug in this
class in the absence of a diagnostic encounter likely repre-
sents continued therapy without documentation of fol-
low-up treatment.
These findings underscore that caution must be exercized
by healthcare providers in prescribing mefloquine to
deploying U.S. military personnel, and lend strong sup-
port to policies prohibiting the practice of mass-prescrib-
ing mefloquine without an individualized review of
medical records. Given the significant prevalence of its
contraindications, a careful review and screening of avail-
able medical records (including available pharmacy
records) and thorough counseling prior to prescribing
and dispensing mefloquine to U.S. military personnel is
strongly indicated. The use of existing medical and phar-
macosurveillance databases to populate automated deci-
sion-support systems to assist clinicians in identifying
personnel with possible contraindications may improve
the sensitivity of such review and screening. The develop-Malaria Journal 2008, 7:30 http://www.malariajournal.com/content/7/1/30
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ment of such systems would require that the ICD-9CM
codes and medications deemed consistent with a con-
traindication to mefloquine use be formally defined.
This study also highlights the importance of investing in
the further development and testing of alternative anti-
malaria drugs which retain the advantages in compliance
and convenience of the weekly dosing schedule of meflo-
quine. For U.S. service members in whom mefloquine in
contraindicated, tafenoquine may be a promising alterna-
tive [15], both for its schizonticidal activity and its poten-
tial use as terminal prophylaxis against Plasmodium vivax
infection [16].
Although not sharing the particular contraindications of
mefloquine, tafenoquine carries a significant risk of
haemolysis among those with glucose-6-phosphate dehy-
drogenase (G6PD) deficiency syndrome. A recent study
suggests that the prevalence of this contraindication
among deploying U.S. military populations is lower than
that of contraindications to mefloquine found in the
present study, with 2.5% of males and 1.6% of females
deficient for G6PD [17].
In light of this study's findings, upon U.S. Food and Drug
Administration licensure and upon the completion of
studies confirming its safety and suitability for long-term
administration, tafenoquine may prove to be a viable
option to replace mefloquine for routine use in the U.S.
military. Universal screening for G6PD deficiency upon
entry to U.S. military service may be a prudent means of
ensuring the safe administration of this drug and aiding in
the pre-selection of individuals most suited for long-term
deployment to malarious areas.
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